|
|
|
|
Researchers Report Elevated Levels Of T4 Levels Predict Patient Survival In Hepatitis B Virus-related Liver
Regenerx Biopharmaceuticals, Inc.(NYSE Amex:RGN) announced that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin 4 levels were significantly...
|
|
|
OctoPlus' Locteron interim Phase IIb data to be presented at International Liver Congress in April 2010
Drug delivery service company OctoPlus N.V (Euronext: OCTO) announced today that its licensee, Biolex Therapeutics, has been accepted to present interim results from two ongoing Phase IIb studies with Locteron at the 45th Liver Congress being held in...
|
|
|
OctoPlus Announces That Locteron Interim Phase IIb Data Have Been Accepted for Oral and Poster Presentations a
LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- 02/10/10 -- OctoPlus N.V.('OctoPlus' or 'the Company') (AMS: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has been accepted to present interim...
|
|
|
Inhibition of Inducible Nitric Oxide Synthase Prevents Mitochondrial Damage and Improves Survival of Steatotic Partial Liver Grafts
Background.Steatotic liver grafts are excluded for partial liver transplantation because of increased risk of primary nonfunction. Mechanisms underlying the failure of fatty partial liver grafts (FPG) remain unknown. This study...
|
|
|
Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation
Background.Hepatitis-E virus (HEV) infection can be responsible for chronic hepatitis in solid-organ transplant patients. Methods. We identified 33 cases of autochthonous acute HEV infection in solid-organ transplant patients. Results. Among 27 HEV...
|
|
|
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); COLUMBIA, Md., Feb.10 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox...
|
|
|
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
270 patients treated in Phase III trial at 60 sites in 11 countries COLUMBIA, Md., Feb.10 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III...
|
|
|
Medical News: Researchers Report Elevated Levels Of T4 Levels Predict Patient Survival In Hepatitis B Virus-related Liver Failure
Regenerx Biopharmaceuticals, Inc.(NYSE Amex:RGN) announced that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus-related liver failure. Medical News: Researchers Report Elevated Levels Of T4 Levels...
|
|
|
A useful tool to diagnose primary biliary cirrhosis
Autoimmune Diseases Breaking News EUREKALERT Contact: Ye-Ru Wang 86-105-908-0039 Previous studies have shown that assessment of immunoglobulin subclasses in plasma cells by immunohistochemistry (IHC) may be useful in the histopathologic evaluation of autoimmune...
|
|
|
Hepatitis C self-care
If you have hepatitis C your doctor needs to keep close watch on your liver function.iStockphoto.com/Lilli Day Also on the Web myOptumHealth.com tools More from myOptumHealth More>> Health More>> Latest Health News More>> Content...
|
|
|
Thymosin 4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection
REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin 4 levels were...
|
|
|
Entecavir (Baraclude) Improves Liver Function in Chronic Hepatitis B Patients with Decompensated Cirrhosis
Over years or decades, can progress to advanced liver disease including cirrhosis (scarring) and hepatocellular carcinoma.Compensated cirrhosis means the liver is heavily damaged but can still carry out its normal functions; decompensated...
|
|
|
Health Discovery and New York City Pancreatic Cancer Center form ...
Company: Health Discovery Corp (HDVY) Health Discovery, a molecular diagnostics company, has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to...
|
|
|
Health Discovery and New York City Pancreatic Cancer Center form partnership
Health Discovery, a molecular diagnostics company, has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests...
|
|
|
Health 101:Which hospital specializes in treating cancers of the pancreas and biliary system
Saint Vincent Catholic Medical Centers(logo) Google Images If you like this ...Did you know that 1 in 72 men and women are diagnosed with cancer of the pancreas during their lifetime? The Pancreas, Biliary and Liver Surgery Center at Saint Vincent...
|
|
|
FDA liver risk warning for Bristol-Myers HIV drug
Federal health officials said Monday that patients taking a Bristol-Myers Squibb drug for HIV are at risk of a rare, but potentially fatal, liver disorder.The Food and Drug Administration said it has received 42 reports of the disorder since Videx was...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial of CTS-1027 in Combination With Pegylated Interferon
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Dentistry: Recent findings from University of Suleyman Demirel highlight research in dentistry
Today's Medical & Research News Dentistry Recent findings from University of Suleyman Demirel highlight research in dentistry February 9th, 2010 Printer-Friendly Version City:Isparta Country:Turkey Dentistry Drug Development Gastroenterology Hematology...
|
|
|
Researchers Report Elevated Levels of T4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
T4 - Potential New Therapeutic Agent for Liver Failure REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus-related liver failure....
|
|
|
Researchers Report Elevated Levels of T4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver
T4 Potential New Therapeutic Agent for Liver Failure BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus...
|
|
|
Researchers Report Elevated Levels of T4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver
T4 Potential New Therapeutic Agent for Liver Failure BETHESDA, Md.--(BUSINESS WIRE)--Feb 8, 2010 - REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with...
|
|
|
Researchers Report Elevated Levels of T4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
T4 Potential New Therapeutic Agent for Liver Failure BETHESDA, Md.(BUSINESS WIRE) REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus...
|
|
|
Researchers Report Elevated Levels of T4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
T4 Potential New Therapeutic Agent for Liver Failure BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC.(NYSE Amex:RGN) announced today that researchers have correlated T4 levels with the clinical course of patients with hepatitis B virus...
|
|
|
Researchers Report Elevated Levels of TB4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver F
Potential New Therapeutic Agent for Liver Failure ) BETHESDA, Md., Feb 08, 2010 (BUSINESS WIRE) -- REGENERX BIOPHARMACEUTICALS, INC.(NYSE AMEX:RGN) announced today that researchers have correlated TB4 levels with the clinical course of patients with...
|
|
|
Researchers Report Elevated Levels of T4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
T4 Potential New Therapeutic Agent for Liver Failure Buzz up!Companies: Related Quotes {"s" : "rgn","k" : "c10,l10,p20,t10","o" : "","j" : ""} BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC! (NYSE Amex:RGN) announced today that...
|
